FDA requires low doses in testing, so 1mg and 2mg were mandatory, and their inefficacy versus placebo resulted in the stock bombing; this totally overshadowed the positives behind the 5mg dose's significance. While some are saying it was poor judgement on CARA's part to implement these low dose levels, these individuals are ill-informed of the industry. The results of this phase were FINE- no better no worse- and we will see a larger dose(s) applied in the next phase.
While the sell off was totally over done, i must admit, the buying leading up to these results was almost equally overdone. The share price should sit around $20 IMO, and i will continue to accumulate at this level, because i think CR845's efficacy in pruritus alone warrants investor's attention and respect. The market share CARA stands to acquire for itch alone is huge. I believe firmly that any wins CR845 endures against pain should be viewed as supplemental to this drug and this company's long-term potential.
I wont be going anywhere.
Good look to all.
News 
Market Data 
Discover 
AI
